Table 3.

Effects of 6-week treatment with Ganoderma lucidum or placebo on HRQoL in women with fibromyalgia. Analysis of the participants who completed the study ^a.

Outcome measurements	Baseline (Mean ± SD)	After 6 Weeks’ Treatment (Mean ± SD)	p *	Treatment Effect. Mean (95% CI)	p **
SF12v2 (n = 50; GLG = 26; PG = 24)
Physical Function
GLG	39.42 ± 37.53	47.12 ± 31.09	0.175	5.61 (from −10.48 to 21.70)	0.487
PG	41.67 ± 24.08	43.75 ± 35.55	0.723
Physical Role
GLG	52.88 ± 31.29	62.50 ± 28.06	0.106	1.8 (from −14.76 to 18.37)	0.828
PG	46.35 ± 22.57	54.17 ± 27.00	0.200
Bodily Pain
GLG	40.38 ± 39.42	56.73 ± 29.63	0.047	10.10 (from −9.64 to 29.84)	0.309
PG	40.63 ± 31.98	46.88 ± 25.87	0.283
General Health
GLG	17.50 ± 22.55	30.00 ± 25.22	0.015	4.58 (from −9.13 to 18.29)	0.505
PG	27.08 ± 22.98	35.00 ± 21.37	0.118
Vitality
GLG	30.77 ± 31.07	38.46 ± 32.58	0.319	−7.93 (from −26.88 to 11.02)	0.404
PG	26.04 ± 23.86	41.67 ± 20.41	0.008
Social Functioning
GLG	51.92 ± 37.36	72.11 ± 38.94	0.030	13.94 (from −10.23 to 38.11)	0.252
PG	56.25 ± 37.77	62.50 ± 36.11	0.450
Emotional Role
GLG	61.06 ± 28.79	75.48 ± 26.81	0.033	5.57 (from −12.52 to 23.66)	0.539
PG	59.90 ± 27.82	68.75 ± 26.58	0.174
Mental Health
GLG	39.90 ± 25.25	59.61 ± 25.32	0.001	6.17 (from −7.61 to 19.95)	0.373
PG	47.91 ± 19.39	61.46 ± 17.64	0.008
Standardized Physical Component
GLG	34.31 ± 9.89	37.31 ± 10.70	0.104	2.24 (from −2.88 to 7.37)	0.383
PG	34.55 ± 7.48	35.31 ± 9.21	0.681
Standardized Mental Component
GLG	39.46 ± 10.57	46.33 ± 13.20	0.011	−0.06 (from −6.66 to 6.65)	0.987
PG	39.83 ± 9.65	46.76 ± 9.54	0.003

^a Values are expressed in points. * p: values of t-test for the intragroup analysis. ** p: values for the analysis of variance for repeated measures to compare the difference between groups after 6 weeks′ treatment (after applying the Bonferroni correction, p < 0.004). SF12v2: Short-Form Health Survey 12 version 2; GLG: Ganoderma lucidum group; PG: placebo group.